The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
1 to 10 of 2150    Next 10 >    Last >>
Add to Report ID Question Status Last Updated
20190082

Primary site/Histology--Peritoneum: What is the correct primary site code for peritoneal mesothelioma in a female? When I use C482, it seems that the fields are all geared towards primary peritoneal carcinoma with FIGO staging, etc.

Final Oct 15 2019
20190081

Race:  How is race coded for a patient who self-reports as white? In the Family History portion of the genetics consult, it states the maternal family is of mixed European and Cherokee descent; the paternal side is of mixed German/mixed European descent. Is race coded as Race 1: 03-American Indian and Race 2: 01-White, or as 01-White according to self-report by the patient?

Final Oct 15 2019
20190080

Update to current manual/Surgery of Primary Site/Surgery codes--Melanoma:  Can the operative report be used to assess margins if there is no residual melanoma on the wide excision and no margins stated, or if distance is not stated on the pathology report when there is residual melanoma?  See Discussion.

 

Final Oct 15 2019
20190079

Reportability/Histology--Pancreas:  Is mucinous cystic neoplasm of pancreas reportable?

Final Oct 15 2019
20190078

Histology/Brain and CNS: What is the histology code for subcortical bubbly T2 hyperintense lesions in the left temporal lobe most consistent with multinodular vacuolating neuronal tumor (MVNT) from a MRI of the brain in 2018. Is the best histology code to use for this tumor 8000/1?  See Discussion.

Final Oct 15 2019
20190077

Summary Stage 2018/EOD 2018:  How should SEER Summary Stage 2018 be coded for a 2018 thymus primary which has mediastinal fat invasion without mediastinal pleural involvement? See Discussion.

Final Oct 15 2019
20190076

Primary Site/Brain and CNS: How is primary site coded when the ICD-O-3 provides a sub-site-associated morphology code and the only information available to code primary site for a particular diagnosis indicates a non-specific/not otherwise specified (NOS) site code?  See Discussion.

Final Oct 10 2019
20190075

Sex: How should the sex field be coded for the newly allowable non-binary gender designation Gender X? See Discussion.
 

Final Oct 10 2019
20190074

First course treatment/Scope of Reg LN Surgery--Breast: How is Scope of Regional Lymph Node Surgery coded when there is a sentinel lymph node biopsy (SLNBx) and intra-mammary nodes removed for a single primary? See Discussion.

Final Oct 10 2019
20190073

Solid Tumor Rules (2018)/Multiple primaries--Lung: How many primaries should be reported for a patient with a March 2018 diagnosis of non-small cell carcinoma with neuroendocrine differentiation on lung biopsy (single left upper lobe tumor only) who also has a prior history of left lung squamous cell carcinoma in 2016 (treated with chemotherapy/radiation)? See Discussion.

 

Final Oct 10 2019
Next 10 >